Holley, Caroline L. https://orcid.org/0000-0002-2231-0136
Monteleone, Mercedes https://orcid.org/0000-0003-0777-3965
Fisch, Daniel https://orcid.org/0000-0002-8155-0367
Libert, Alexandre E. S. https://orcid.org/0009-0005-7299-2672
Ju, Robert J. https://orcid.org/0000-0002-9850-9803
Choi, Joon H. https://orcid.org/0000-0003-4254-0286
Condon, Nicholas D.
Emming, Stefan https://orcid.org/0000-0002-3851-335X
Crawford, Joanna
Lawrence, Grace M. E. P.
Coombs, Jared R. https://orcid.org/0000-0002-1703-1247
Lefevre, James G. https://orcid.org/0000-0002-5945-9575
Bajracharya, Rinie
Lahoud, Mireille H. https://orcid.org/0000-0001-8472-6201
Yap, Alpha S.
Hamilton, Nicholas
Stehbens, Samantha J.
Kagan, Jonathan C. https://orcid.org/0000-0003-2364-2746
Ariotti, Nicholas https://orcid.org/0000-0003-3901-0831
Burgener, Sabrina S. https://orcid.org/0000-0002-9332-7998
Schroder, Kate https://orcid.org/0000-0001-9261-3805
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2009075, GNT113659)
Department of Education and Training | Australian Research Council (DP230100300, DP230100300, DE200101300, DE220100823, FT190100516)
University of Queensland (n/a)
Yulgilbar Alzheimer’s Foundation
Human Frontier Science Program (LT0006/2022-L)
European Molecular Biology Organization (ALTF 491-2022)
Silicon Valley Community Foundation (2020-225648)
U.S. Department of Health & Human Services | National Institutes of Health (AI167993, AI11655, DK34854)
Novartis Foundation
Article History
Received: 21 October 2023
Accepted: 24 October 2024
First Online: 4 December 2024
Competing interests
: K.S., M.H.L. and J.C.K. declare the following competing interests: K.S. is a coinventor on patent applications for NLRP3 inhibitors that have been licensed to Inflazome Ltd. K.S. served on the Scientific Advisory Board of Inflazome (2016–2017) and Quench Bio, USA (2018–2021) and serves on a Scientific Advisory Board for Novartis, Switzerland (since 2020). M.H.L. is an inventor on patents relating to CLEC9A antibodies. J.C.K. consults and holds equity in Corner Therapeutics, Larkspur Biosciences, MindImmune Therapeutics and Neumora Therapeutics; none of these relationships affected this study. The other authors declare no competing interests.